The risk of ischemic stroke in major rheumatic disorders

Journal of Neuroimmunology

Volumn 277, Issue 1-2, 2014, Pages 1-5

  Behrouz, Réza ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Ankylosing spondylitis; Ischemic stroke; Psoriatic arthritis; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

ANTICOAGULANT AGENT; ANTIMALARIAL AGENT; ANTITHROMBOCYTIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; GOLIMUMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CLINICAL FEATURE; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; HIGH RISK POPULATION; HUMAN; HYPERCOAGULABILITY; INFLAMMATION; NEUROPATHOLOGY; PSORIATIC ARTHRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK REDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; ANIMAL; COMPLICATION; ISCHEMIA; RHEUMATIC DISEASES; RISK FACTOR; STROKE;

ANIMALS; HUMANS; ISCHEMIA; RHEUMATIC DISEASES; RISK FACTORS; STROKE;

EID: 84918841014     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.09.009     Document Type: Review

References (75)

1. Akimoto T., Kobayashi S., Tamura N., Ohsawa T., Kawano T., Tanaka M., Hashimoto H. Risk factors for recurrent thrombosis: prospective study of a cohort of Japanese systemic lupus erythematosus. Angiology 2005, 56:601-609.
2. Al Husain A., Bruce I.N. Risk factors for coronary heart disease in connective tissue diseases. Ther. Adv. Musculoskelet. Dis. 2010, 2:145-153.
3. Al-Herz A., Ensworth S., Shojania K., Esdaile J.M. Cardiovascular risk factor screening in systemic lupus erythematosus. J. Rheumatol. 2003, 30:493-496.
4. Altman R.S. Chapter 35: joint disorders. The Merck Manual of Diagnosis and Therapy 2011, 297-310. Merck Sharp and Dohme, Whitehouse Station. 19th edition. R.S. Porter, J.L. Kaplan (Eds.).
5. Asherson R.A., Khamashta M.A., Gil A., Vazquez J.J., Chan O., Baguley E., Hughes G.R. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. Am. J. Med. 1989, 86:391-399.
6. Aviña-Zubieta J.A., Choi H.K., Sadatsafavi M., Etminan M., Esdaile J.M., Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008, 59:1690-1697.
7. Bacani A.K., Gabriel S.E., Crowson C.S., Heit J.A., Matteson E.L. Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events?. Arthritis Rheum. 2012, 64:53-61.
8. Bäck M., Yin L., Ingelsson E. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. Eur. Heart J. 2012, 33:1928-1933.
9. Bay-Jensen A.C., Leeming D.J., Kleyer A., Veidal S.S., Schett G., Karsdal M.A. Ankylosing spondylitis is characterized by an increased turnover of several different metalloproteinase-derived collagen species: a cross-sectional study. Rheumatol. Int. 2012, 32:3565-3572.
10. Bertsias G.K., Ioannidis J.P., Aringer M., Bollen E., Bombardieri S., Bruce I.N., Cervera R., Dalakas M., Doria A., Hanly J.G., Huizinga T.W., Isenberg D., Kallenberg C., Piette J.C., Schneider M., Scolding N., Smolen J., Stara A., Tassiulas I., Tektonidou M., Tincani A., van Buchem M.A., van Vollenhoven R., Ward M., Gordon C., Boumpas D.T. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann. Rheum. Dis. 2010, 69:2074-2082.
11. Bessant R., Hingorani A., Patel L., MacGregor A., Isenberg D.A., Rahman A. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford) 2004, 43:924-929.
12. Dakwar E., Reddy J., Vale F.L., Uribe J.S. A review of the pathogenesis of ankylosing spondylitis. Neurosurg. Focus. 2008, 24:E2. 10.3171/FOC/2008/24/1/E2.
13. Del Rincón I., Polak J.F., O'Leary D.H., Battafarano D.F., Erikson J.M., Restrepo J.F., Molina E., Escalante A. Systemic inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis. Ann. Rheum. Dis. 2014, 10.1136/annrheumdis-2013-205058.
14. Eder L., Thavaneswaran A., Chandran V., Cook R., Gladman D.D. Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis. Ann. Rheum. Dis. 2014, 10.1136/annrheumdis-2014-205267.
15. El Maghraoui Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur. J. Intern. Med. 2011, 22:554-560.
16. Ersozlu Bozkirli E.D., Bozkirli E., Yucel A.E. Effects of infliximab treatment in terms of cardiovascular risk and insulin resistance in ankylosing spondylitis patients. Mod. Rheumatol. 2014, 24:335-339.
17. Esdaile J.M., Abrahamowicz M., Grodzicky T., Li Y., Panaritis C., du Berger R., CÔte R., Grover S.A., Fortin P.R., Clarke A.E., Senécal J.L. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001, 44:2331-2337.
18. Favarato M.H., Mease P., Gonçalves C.R., Gonçalves Saad C., Sampaio-Barros P.D., Goldenstein-Schainberg C. Hypertension and diabetes significantly enhance the risk of cardiovascular disease in patients with psoriatic arthritis. Clin. Exp. Rheumatol. 2014, 32:182-187.
19. Fluture A., Chaudhari S., Frishman W.H. Valvular heart disease and systemic lupus erythematosus: therapeutic implications. Heart Dis. 2003, 5:349-353.
20. Futrell N., Millikan C. Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus. Stroke 1989, 20:583-591.
21. Gelfand J.M., Gladman D.D., Mease P.J., Smith N., Margolis D.J., Nijsten T., Stern R.S., Feldman S.R., Rolstad T. Epidemiology of psoriatic arthritis in the population of the United States. J. Am. Acad. Dermatol. 2005, 53:573.
22. Genre F., López-Mejías R., Miranda-Filloy J.A., Carnero-López B., Gómez-Acebo I., Blanco R., Ochoa R., Rueda J., González-Juanatey C., Llorca J., González-Gay M.Á. Correlation between insulin resistance and serum ghrelin in non-diabetic ankylosing spondylitis patients undergoing anti-TNF-α therapy. Clin. Exp. Rheumatol. 2013, 31:913-918.
23. Gupta N., Saigal R., Goyal L., Agrawal A., Bhargava R., Agrawal A. Carotid intima media thickness as a marker of atherosclerosis in ankylosing spondylitis. Int. J. Rheumatol. 2014, 2014:839135. 10.1155/2014/839135.
24. Hajj-ali R.A. Chapter 33: autoimmune rheumatic disorders. The Merck Manual of Diagnosis and Therapy 2011, 332-348. Merck Sharp and Dohme, Whitehouse Station. 19th edition. R.S. Porter, J.L. Kaplan (Eds.).
25. Hamdi W., Chelli Bouaziz M., Zouch I., Ghannouchi M.M., Haouel M., Ladeb M.F., Kchir M.M. Assessment of preclinical atherosclerosis in patients with ankylosing spondylitis. J. Rheumatol. 2012, 39:322-326.
26. Hojnik M., George J., Ziporen L., Shoenfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 1996, 93:1579-1587.
27. Horreau C., Pouplard C., Brenaut E., Barnetche T., Misery L., Cribier B., Jullien D., Aractingi S., Aubin F., Joly P., Le Maître M., Ortonne J.P., Paul C., Richard M.A. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J. Eur. Acad. Dermatol. Venereol. 2013, 27(Suppl. 3):12-29.
28. Jennekens F.G., Kater L. The central nervous system in systemic lupus erythematosus. Part 2. Pathogenetic mechanisms of clinical syndromes: a literature investigation. Rheumatology (Oxford) 2002, 41:619-630.
29. Johnsen S.P., Larsson H., Tarone R.E., McLaughlin J.K., Nørgård B., Friis S., Sørensen H.T. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch. Intern. Med. 2005, 165:978-984.
30. Keller J.J., Hsu J.L., Lin S.M., Chou C.C., Wang L.H., Wang J., Bai C.H., Chiou H.Y. Increased risk of stroke among patients with ankylosing spondylitis: a population-based matched-cohort study. Rheumatol. Int. 2014, 34:255-263.
31. Khamashta M.A., Cuadrado M.J., Mujic F., Taub N.A., Hunt B.J., Hughes G.R. The management of thrombosis in the antiphospholipid-antibody syndrome. N. Engl. J. Med. 1995, 332:993-997.
32. Kitagawa Y., Gotoh F., Koto A., Okayasu H. Stroke in systemic lupus erythematosus. Stroke 1990, 21:1533-1539.
33. Koerner C., Sommer C., Knauth M., Breitbart A., Wildemann B. Granulomatous cerebral vasculitis in systemic lupus erythematosus during systemic remission of disease. J. Neurol. 2000, 247:722-724.
34. Krishnan E. Stroke subtypes among young patients with systemic lupus erythematosus. Am. J. Med. 2005, 118:1415.
35. Levine J.S., Branch W., Rauch J. The antiphospholipid syndrome. NEJM 2002, 346:752-762.
36. Lin C.W., Huang Y.P., Chiu Y.H., Ho Y.T., Pan S.L. Increased risk of ischemic stroke in young patients with ankylosing spondylitis: a population-based longitudinal follow-up study. PLoS One 2014, 9(4):e94027. (Apr 8).
37. Lindhardsen J., Ahlehoff O., Gislason G.H., Madsen O.R., Olesen J.B., Svendsen J.H., Torp-Pedersen C., Hansen P.R. Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study. BMJ 2012, 344:e1257.
38. Lindhardsen J., Gislason G.H., Jacobsen S., Ahlehoff O., Olsen A.M., Madsen O.R., Torp-Pedersen C., Hansen P.R. Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann. Rheum. Dis. 2013, 10.1136/annrheumdis-2012-203137.
39. Love P.E., Santoro S.A. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann. Intern. Med. 1990, 112:682-698.
40. Mathieu S., Motreff P., Soubrier M. Spondyloarthropathies: an independent cardiovascular risk factor?. Joint Bone Spine 2010, 77:542-545.
41. McCarey D., Sturrock R.D. Comparison of cardiovascular risk in ankylosing spondylitis and rheumatoid arthritis. Clin. Exp. Rheumatol. 2009, 27:S124-S126.
42. McGettigan P., Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011, 8:e1001098. 10.1371/journal.pmed.1001098.
43. Mikdashi J., Handwerger B., Langenberg P., Miller M., Kittner S. Baseline disease activity, hyperlipidemia, and hypertension are predictive factors for ischemic stroke and stroke severity in systemic lupus erythematosus. Stroke. 2007 Feb, 38(2):281-285.
44. Miranda-Filloy J.A., Llorca J., Carnero-López B., González-Juanatey C., Blanco R., González-Gay M.A. TNF-alpha antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients. Clin. Exp. Rheumatol. 2012, 30:850-855.
45. Moyssakis I., Tektonidou M.G., Vasilliou V.A., Samarkos M., Votteas V., Moutsopoulos H.M. Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. Am. J. Med. 2007, 120:636-642.
46. Myasoedova E., Crowson C.S., Kremers H.M., Therneau T.M., Gabriel S.E. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum. 2010, 62:1576-1582.
47. Nadareishvili Z., Michaud K., Hallenbeck J.M., Wolfe F. Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis Rheum. 2008, 59:1090-1096.
48. Naranjo A., Sokka T., Descalzo M.A., Calvo-Alén J., Hørslev-Petersen K., Luukkainen R.K., Combe B., Burmester G.R., Devlin J., Ferraccioli G., Morelli A., Hoekstra M., Majdan M., Sadkiewicz S., Belmonte M., Holmqvist A.C., Choy E., Tunc R., Dimic A., Bergman M., Toloza S., Pincus T., QUEST-RA Group Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res. Ther. 2008, 10:R30.
49. Nikpour M., Gladman D.D., Urowitz M.B. Premature atherosclerosis in systemic lupus erythematosus. Lupus 2013, 22:1243-1250.
50. Nurmohamed M.T., van der Horst-Bruinsma I., Maksymowych W.P. Cardiovascular and cerebrovascular diseases in ankylosing spondylitis: current insights. Curr. Rheumatol. Rep. 2012, 14:415-421.
51. Roldan C.A., Gelgand E.A., Qualls C.R., Sibbitt W.L. Valvular heart disease as a cause of cerebrovascular disease in patients with systemic lupus erythematosus. Am. J. Cardiol. 2005, 95:1441-1447.
52. Roldan C.A., Sibbitt W.L., Qualls C.R., Jung R.E., Greene E.R., Gasparovic C.M., Hayek R.A., Charlton G.A., Crookston K. Libman-Sacks endocarditis and embolic cerebrovascular disease. JACC Cardiovasc. Imaging 2013, 6:973-983.
53. Ruiz-Irastorza G., Egurbide M.V., Pijoan J.I., Garmendia M., Villar I., Martinez-Berriotxoa A., Erdozain J.G., Aguirre C. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006, 15:577-583.
54. Ruiz-Irastorza G., Hunt B.J., Khamashta M.A. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007, 57:1487-1495.
55. Saadatnia M., Sayed-Bonakdar Z., Mohammad-Sharifi G., Sarrami A.H. Prevalence and prognosis of cerebrovascular accidents and its subtypes among patients with systemic lupus erythematosus in Isfahan, Iran: a hospital clinic-based study. Int. J. Prev. Med. 2014, 5:123-126.
56. Sieper J., Rudwaleit M., Khan M.A., Braun J. Concepts and epidemiology of spondyloarthritis. Best Pract. Res. Clin. Rheumatol. 2006, 20:401-417.
57. Södergren A., Stegmayr B., Ohman M.L., Wållberg-Jonsson S. Increased incidence of stroke and impaired prognosis after stroke among patients with seropositive rheumatoid arthritis. Clin. Exp. Rheumatol. 2009, 27:641-644.
58. Sofat N., Malik O., Higgens C.S. Neurological involvement in patients with rheumatic disease. QJM 2006, 99:69-79.
59. Solomon D.H., Goodson N.J., Katz J.N., Weinblatt M.E., Avorn J., Setoguchi S., Canning C., Schneeweiss S. Patterns of cardiovascular risk in rheumatoid arthritis. Ann. Rheum. Dis. 2006, 65:1608-1612.
60. Szabo S.M., Levy A.R., Rao S.R., Kirbach S.E., Lacaille D., Cifaldi M., Maksymowych W.P. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum. 2011, 63:3294-3304.
61. Tam L.S., Shang Q., Li E.K., Tomlinson B., Chu T.T., Li M., Leung Y.Y., Kwok L.W., Wong K.C., Li T.K., Yu T., Zhu T.Y., Kun E.W., Yip G.W., Yu C.M. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum. 2008, 59:1322-1331.
62. Tam L.S., Tomlinson B., Chu T.T., Li M., Leung Y.Y., Kwok L.W., Li T.K., Yu T., Zhu Y.E., Wong K.C., Kun E.W., Li E.K. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls-the role of inflammation. Rheumatology (Oxford) 2008, 47:18-723.
63. Timlin H., Petri M. Transient ischemic attack and stroke in systemic lupus erythematosus. Lupus 2013, 22:1251-1258.
64. Turesson C., Matteson E.L. Management of extra-articular disease manifestations in rheumatoid arthritis. Curr. Opin. Rheumatol. 2004, 16:206-211.
65. Turiel M., Sarzi-Puttini P., Peretti R., Bonizzato S., Muzzupappa S., Atzeni F., Rossi E., Doria A. Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. Am. J. Cardiol. 2005, 96:574-579.
66. Tyrrell P.N., Beyene J., Feldman B.M., McCrindle B.W., Silverman E.D., Bradley T.J. Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1014-1026.
67. Varas-Lorenzo C., Riera-Guardia N., Calingaert B., Castellsague J., Pariente A., Scotti L., Sturkenboom M., Perez-Gutthann S. Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol. Drug Saf. 2011, 20:1225-1236.
68. Vaudo G., Marchesi S., Gerli R., Allegrucci R., Giordano A., Siepi D., Pirro M., Shoenfeld Y., Schillaci G., Mannarino E. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann. Rheum. Dis. 2004, 63:31-35.
69. Ward M.M. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 1999, 42:338-346.
70. Wasko M.C., Hsia E.C., Kirkham B., Touboul P.J., Fleischmann R., Genovese M.C., Matteson E.L., Lu J., Xu W., Rahman M.U. Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritides. J. Clin. Rheumatol. 2014, 20:1-10.
71. Wilson F.C., Icen M., Crowson C.S., McEvoy M.T., Gabriel S.E., Kremers H.M. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J. Rheumatol. 2009, 36:361-367.
72. Woo K.S., Kim K.E., Kim J.M., Han J.Y., Chung W.T., Kim K.H. Prevalence and clinical associations of lupus anticoagulant, anticardiolipin antibodies, and anti-beta2-glycoprotein I antibodies in patients with systemic lupus erythematosus. Korean J. Lab. Med. 2010, 30:38-44.
73. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am. J. Clin. Dermatol. 2003, 4:441-447.
74. Zhang J., Chen L., Delzell E., Muntner P., Hillegass W.B., Safford M.M., Millan I.Y., Crowson C.S., Curtis J.R. The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2014, 73:1301-1308.
75. Zhu T.Y., Li E.K., Tam L.S. Cardiovascular risk in patients with psoriatic arthritis. Int. J. Rheumatol. 2012, 2012:714321. 10.1155/2012/714321.